Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Inhye Park has been awarded a Novo Nordisk Postdoctoral Research Fellowship to research the biology of resident vascular macrophages in atherosclerosis.

Inhye Park

Atherosclerosis is a chronic inflammatory disease that causes the build-up of plaques in the artery walls and is the underlying cause of cardiovascular mortality. Inhye’s fellowship will allow her to investigate the mechanism of action of resident macrophages in the artery, which are thought to alleviate inflammation and facilitate cholesterol metabolism in the vessel wall. She will use bioinformatics methods for target discovery and in vitro and in vivo validation using iPSC-derived macrophages and murine models for her new project.

“If we can identify the molecular mechanism that regulates athero-protective properties in resident vascular macrophages, we can use this to identify new potential therapeutic targets for attenuating atherogenesis. This is a huge opportunity to address one of the leading causes of cardiovascular mortality and I’m grateful to Novo Nordisk for their support of this project,” said Inhye. 

The project is a collaboration between the Kennedy Institute of Rheumatology and the Novo Nordisk Research Centre Oxford.

Similar stories

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

Welcome to the new Kennedy Trust CEO

The Kennedy Trust has announced Dr Stephen Simpson as its new Chief Executive Officer from 1 July 2022.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.